Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;17(2):79-92.
doi: 10.1038/nrc.2016.126. Epub 2017 Jan 4.

Consensus Molecular Subtypes and the Evolution of Precision Medicine in Colorectal Cancer

Affiliations
Review

Consensus Molecular Subtypes and the Evolution of Precision Medicine in Colorectal Cancer

Rodrigo Dienstmann et al. Nat Rev Cancer. .

Erratum in

Abstract

Critical driver genomic events in colorectal cancer have been shown to affect the response to targeted agents that were initially developed under the 'one gene, one drug' paradigm of precision medicine. Our current knowledge of the complexity of the cancer genome, clonal evolution patterns under treatment pressure and pharmacodynamic effects of target inhibition support the transition from a one gene, one drug approach to a 'multi-gene, multi-drug' model when making therapeutic decisions. Better characterization of the transcriptomic subtypes of colorectal cancer, encompassing tumour, stromal and immune components, has revealed convergent pathway dependencies that mandate a 'multi-molecular' perspective for the development of therapies to treat this disease.

Similar articles

See all similar articles

Cited by 124 articles

See all "Cited by" articles

References

    1. Nat Commun. 2015 Sep 22;6:8305 - PubMed
    1. Clin Cancer Res. 2015 May 1;21(9):2157-66 - PubMed
    1. BMC Cancer. 2012 Jun 19;12:260 - PubMed
    1. PLoS Genet. 2014 Mar 27;10 (3):e1004271 - PubMed
    1. Sci Transl Med. 2015 Jan 28;7(272):272ra12 - PubMed
Feedback